Distinguished in Low Blood Sugar

Ulrike Hovelmann

Neuss, NW, DE 
Distinguished in Low Blood Sugar
Neuss, NW, DE 
OverviewLocationsClinical Research

Overview

Ulrike Hovelmann practices in Neuss, Germany. Ms. Hovelmann is rated as a Distinguished expert by MediFind in the treatment of Low Blood Sugar. Her top areas of expertise are Low Blood Sugar, Type 1 Diabetes (T1D), Type 2 Diabetes (T2D), and Chronic Erosive Gastritis.

Her clinical research consists of co-authoring 20 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 6 articles in the study of Low Blood Sugar.

Gender
Female

Locations

Neuss, NW, Germany
Other Locations
Mainz, RP 55116, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A First-in-human, Randomised, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects
A First-in-human, Randomised, Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZP8396 Administered to Healthy Subjects
Enrollment Status: Completed
Publish Date: January 17, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of ZP7570 in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of ZP7570 in Healthy Subjects
Enrollment Status: Completed
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Early Phase 1
Randomised, Sequential, Cross-over Trial Assessing PK and PD Responses After Micro-doses of ZP4207 Administered s.c. to Patients With T1D Under eu- and Hypoglycemic Conditions and With Reference to Freshly Reconstituted Lyophilized Glucagon
Randomised, Sequential, Cross-over Trial Assessing PK and PD Responses After Micro-doses of ZP4207 Administered s.c. to Patients With T1D Under eu- and Hypoglycemic Conditions and With Reference to Freshly Reconstituted Lyophilized Glucagon
Enrollment Status: Completed
Publish Date: April 21, 2017
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

20 Total Publications

Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetes.
Journal: Diabetes, obesity & metabolism
Published: November 28, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hovelmann's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile